 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 9145 | 回復(fù): 6 | ||
| 當前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | ||
星海慧兒榮譽版主 (職業(yè)作家)
木蟲精靈
|
[求助]
請教RLD和RS的區(qū)別 已有1人參與
|
|
|
在FDA上看到一個產(chǎn)品有RLD也有RS，但是兩者不一個廠家，請教RLD和RS到底有何區(qū)別，單從字面講，似乎RS更令人困惑。 MYLAN的是RS，但不是RLD；ASTRA的在橙皮書檢索下是RLD，但在drugs@FDA搜索出來的RLD項下又都是NO，很困惑，求解。 1.png 2.png |
回復(fù)此樓» 猜你喜歡
SPguide®：小鼠體內(nèi)脾臟轉(zhuǎn)染的一鍵解決方案
已經(jīng)有0人回復(fù)
-
高效肺靶向RNA轉(zhuǎn)染，加速肺部RNA藥物開發(fā)
已經(jīng)有2人回復(fù)
-
藥理學論文潤色/翻譯怎么收費?
已經(jīng)有162人回復(fù)
-
二糖的糖脂，合成后sephadex LH-20分離不出來，求助
已經(jīng)有1人回復(fù)
-
南方醫(yī)科大學珠江醫(yī)院肖計生課題組招收博士生 （2026年入學）
已經(jīng)有2人回復(fù)
-
349藥學專碩105500求調(diào)劑
已經(jīng)有0人回復(fù)
-
求調(diào)劑
已經(jīng)有1人回復(fù)
-
298求調(diào)劑一志愿中海洋
已經(jīng)有3人回復(fù)
-
藥學調(diào)劑申請自薦信，一志愿中南大學
已經(jīng)有1人回復(fù)
-
藥學349專碩求調(diào)劑
已經(jīng)有1人回復(fù)
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復(fù)
小朋友681
木蟲 (正式寫手)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 3370.3
- 散金: 60
- 紅花: 3
- 帖子: 785
- 在線: 200小時
- 蟲號: 553909
- 注冊: 2008-05-05
- 性別: GG
- 專業(yè): 有機合成
星海慧兒3樓2017-02-19 22:51:53
mouse103
專家顧問 (著名寫手)
- DRDEPI: 16
- 應(yīng)助: 218 (大學生)
- 貴賓: 0.384
- 金幣: 1423.7
- 散金: 2586
- 紅花: 171
- 沙發(fā): 1
- 帖子: 1626
- 在線: 411.4小時
- 蟲號: 466716
- 注冊: 2007-11-24
- 專業(yè): 合成藥物化學
- 管轄: 生物醫(yī)藥區(qū)
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
感謝參與，應(yīng)助指數(shù) +1
星�；蹆�: 金幣+20, ★★★★★最佳答案, 非常感謝！ 2017-02-10 14:57:38
kk1424: 金幣+5 2017-02-10 15:24:33
感謝參與，應(yīng)助指數(shù) +1
星�；蹆�: 金幣+20, ★★★★★最佳答案, 非常感謝！ 2017-02-10 14:57:38
kk1424: 金幣+5 2017-02-10 15:24:33
|
Reference Listed Drug and Reference Standard A reference listed drug (21 CFR 314.3(b)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. Generally, a reference listed drug is a drug product approved in a new drug application under section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an in vivo bioequivalence study required for approval. FDA generally selects a single reference standard that ANDA applicants must use in in vivo bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances (e.g., where the reference listed drug has been withdrawn from sale and an ANDA is selected as the reference standard), the reference listed drug and the reference standard may be different. FDA has identified reference listed drugs in the Prescription Drug Product and OTC Drug Product Lists. Forthcoming, FDA will identify reference listed drugs in the Discontinued Drug Product List. These identified reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate. FDA also has identified in the Prescription Drug Product and OTC Drug Product Lists reference standards to which the in vivo bioequivalence is compared. These identified reference standards represent the FDA’s best judgment at this time as to the appropriate comparator for purposes of in vivo bioequivalence testing. In some instances when a listed drug is not designated as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may ask FDA to designate a reference listed drug for that drug product. Potential applicants should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting such a request. If the request is granted, the listed drug will be designated as a reference listed drug, in which case an ANDA citing the designated reference listed drug may be submitted. Section 1.7, Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements) explains the character coding system (e.g., AB, AB1, AB2, AB3...) for multisource drug products listed under the same heading with two reference listed drugs. A potential applicant should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that potential applicants have adequate information required for in vivo bioequivalence studies, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons. Historically, there were two situations in which two listed drugs that had been shown to be bioequivalent to each other had both been identified by the symbol “+” in the Orange Book. The first situation was when the in vivo determination of bioequivalence is self-evident and a waiver of any in vivo bioequivalence may be granted. The second situation was when the bioequivalence of two listed products may be determined through in vitro methodology. If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an in vivo bioequivalence study submit a controlled correspondence to the Office of Generic Drugs. |
2樓2017-02-10 14:39:16
星�；蹆�
榮譽版主 (職業(yè)作家)
木蟲精靈
- DRDEPI: 17
- 應(yīng)助: 849 (博后)
- 貴賓: 0.978
- 金幣: 22119.4
- 散金: 3714
- 紅花: 103
- 沙發(fā): 5
- 帖子: 3828
- 在線: 803.1小時
- 蟲號: 568253
- 注冊: 2008-06-03
- 專業(yè): 分析化學
- 管轄: 新藥研發(fā)
4樓2017-02-19 23:37:15
星海慧兒
榮譽版主 (職業(yè)作家)
木蟲精靈
- DRDEPI: 17
- 應(yīng)助: 849 (博后)
- 貴賓: 0.978
- 金幣: 22119.4
- 散金: 3714
- 紅花: 103
- 沙發(fā): 5
- 帖子: 3828
- 在線: 803.1小時
- 蟲號: 568253
- 注冊: 2008-06-03
- 專業(yè): 分析化學
- 管轄: 新藥研發(fā)
|
橙皮書里的我也看了，我的情況是:原研有3個規(guī)格，都是RLD，其中最大規(guī)格的同時也被定為了RS。我仿制的是小規(guī)格，那也就是說我仿制的是小規(guī)格的就選對應(yīng)的小規(guī)格的RLD作參比就行？到時候做BE再選被定為RS的大規(guī)格？這樣藥學和BE不就脫節(jié)了嗎？最起碼我也得用大規(guī)格的參比先研究一下溶出，跟仿制的小規(guī)格的對比一下的吧？所以我覺得藥學應(yīng)該選對應(yīng)規(guī)格的同時還行增加大規(guī)格的RS研究，然后BE用大規(guī)格的RS。請大俠指正。 發(fā)自小木蟲Android客戶端 |
5樓2017-02-19 23:47:07
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 288求調(diào)劑，一志愿華南理工大學071005 +5 | ioodiiij 2026-03-17 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 一志愿中國海洋大學，生物學，301分，求調(diào)劑 +5 | 1孫悟空 2026-03-17 | 5/250 |
|
|
|
[考研] 【考研調(diào)劑】化學專業(yè) 281分，一志愿四川大學，誠心求調(diào)劑 +5 | 吃吃吃才有意義 2026-03-19 | 5/250 |
|
|
|
[考研] 招收調(diào)劑碩士 +4 | lidianxing 2026-03-19 | 10/500 |
|
|
|
[考研] 一志愿武漢理工材料工程專碩調(diào)劑 +4 | Doleres 2026-03-19 | 4/200 |
|
|
|
[考研] 286求調(diào)劑 +6 | lemonzzn 2026-03-16 | 10/500 |
|
|
|
[考研] 求材料調(diào)劑 +10 | 隔壁陳先生 2026-03-12 | 10/500 |
|
|
|
[考研] 材料工程專碩調(diào)劑 +5 | 204818@lcx 2026-03-17 | 6/300 |
|
|
|
[考研] 26調(diào)劑/材料/英一數(shù)二/總分289/已過A區(qū)線 +7 | 步川酷紫123 2026-03-13 | 7/350 |
|
|
|
[考研] 材料與化工一志愿南昌大學327求調(diào)劑推薦 +8 | Ncdx123456 2026-03-13 | 9/450 |
|
|
|
[考研] 生物學071000 329分求調(diào)劑 +3 | 我愛生物生物愛?/a> 2026-03-17 | 3/150 |
|
|
|
[考研] 環(huán)境工程調(diào)劑 +8 | 大可digkids 2026-03-16 | 8/400 |
|
|
|
[考研] 334求調(diào)劑 +3 | 志存高遠意在機?/a> 2026-03-16 | 3/150 |
|
|
|
[考博] 26申博 +4 | 八6八68 2026-03-16 | 4/200 |
|
|
|
[考研] [導(dǎo)師推薦]西南科技大學國防/材料導(dǎo)師推薦 +3 | 尖角小荷 2026-03-16 | 6/300 |
|
|
|
[考研] 東南大學364求調(diào)劑 +5 | JasonYuiui 2026-03-15 | 5/250 |
|
|
|
[考研] 藥學383 求調(diào)劑 +3 | 藥學chy 2026-03-15 | 4/200 |
|
|
|
[考研] 070300化學學碩求調(diào)劑 +6 | 太想進步了0608 2026-03-16 | 6/300 |
|
|
|
[考研] 22408總分284求調(diào)劑 +3 | InAspic 2026-03-13 | 3/150 |
|
|
|
[考研] 295求調(diào)劑 +3 | 小匕仔汁 2026-03-12 | 3/150 |
|